News

Anglo-german bioinformation disclosure

Anglo-german bioinformation disclosure

Focusing on the biopharmaceutical engineering industry, Yingde Biological services cover: pharmaceutical engineering design and consulting services; R&d, design, manufacturing and verification of high standard sanitary containers and modular process equipment; Installation and validation services for pharmaceutical plants/workshops. In 2014, he joined Xinhua Medical Group. Through the strong integration of Xinhua Medical Pharmaceutical Technology Group, Yingde Bio-led layout and steady development, and has now become a leading overall solution service provider for pharmaceutical engineering.

28

2021

/

12

Xinhua Medical wonderful appearance at the 61st National Pharmaceutical Machinery Expo

Xinhua Medical wonderful appearance at the 61st National Pharmaceutical Machinery Expo

The 61st (Autumn 2021) National Pharmaceutical Machinery Expo and the 2021 (Autumn) China International Pharmaceutical Machinery Expo (hereinafter referred to as "Pharmaceutical Opportunity") was held in Chengdu on November 2, 2021 in the West China International Expo City.

02

2021

/

11

Xinhua Medical appeared at the 21st China Biologics Annual Conference (CBioPC2021)

Xinhua Medical appeared at the 21st China Biologics Annual Conference (CBioPC2021)

Xinhua Medical Pharmaceutical Technology Group and its subsidiary Yingde Biological were invited to participate in the event. The exhibition of "Biopharmaceutical EPC overall solution" and the "100L bioreactors" carried by the booth attracted a large number of visitors to exchange and consult.

15

2021

/

10

Zhifei Longcoma awarded the honorary title of "Excellent Supplier" of Xinhua Medical-Anglo-German Bio-COVID-19 vaccine project

Zhifei Longcoma awarded the honorary title of "Excellent Supplier" of Xinhua Medical-Anglo-German Bio-COVID-19 vaccine project

On August 7, President Jiang of Zhifei Biologic, Chairman of Zhifei Longcoma Li and Vice General Manager Jiang visited Xinhua Medical-Chengdu Yingde Biologic Production Base to visit and investigate, and awarded Yingde Biologic novel coronavirus vaccine project "excellent supplier" honorary title. Yingde Biological general manager Su Xiaodong, executive deputy general manager Wang Hongli led the company team to participate in the reception activities. At the beginning of the year, in response to the latest national anti-epidemic policy, Zhifei Longkema novel coronavirus phase II preparation expansion project was urgently launched. Yingde Biologic responded quickly, and the production entered a "war state", providing modular system manufacturing integration, automation control and verification services for the expanded production line of the COVID-19 vaccine workshop, including preparation system, sterilization temporary storage system, buffer dispensing system, preparation system, CIP system, etc. At present, the project has basically completed debugging and verification work, and has the hardware conditions for large-scale production of COVID-19 vaccines. Chairman Jiang of Zhifei Biologic and Chairman Li of Zhifei Longcoma awarded the certificate of "Excellent Supplier" of the novel coronavirus vaccine project for Yingde Biologic, and praised advanced individuals such as "excellent design manager", "excellent Project Manager" and "Excellent Construction manager". Zhifei biological leaders understand the British and German biological production process and project organization Since the outbreak of the epidemic, the R&D, production and quality teams of Zhifeilongoma have worked day and night, racing against the clock, to promote the new coronavirus vaccine to market as soon as possible. The recombinant novel coronavirus vaccine (CHO cell) developed and produced by Zhifeilongoma has reached the international advanced level, and is the fourth COVID-19 vaccine approved for emergency use in China. It is also the first recombinant subunit protein vaccine approved for clinical use in the world. In recent years, the cooperation between Zhifei Longkema and Xinhua Medical has become increasingly close, and the smooth cooperation has made the two sides establish a deep foundation of mutual trust and form a good tacit understanding. At present, the new coronavirus variant strains are frequently emerging, and the international epidemic prevention and control is still serious. Xinhua Medical and Zhifei Longoma will respond to the changing challenges through deeper strategic cooperation and shoulder the historic mission.

09

2021

/

08

The half-year meeting of Yingde Biological marketing work was successfully held in Qingcheng Mountain

The half-year meeting of Yingde Biological marketing work was successfully held in Qingcheng Mountain

July 10-11, Yingde biological marketing work semi-annual meeting was successfully held in Qingcheng Houshan, the company's management team and the sales staff of each area gathered together to review and summarize the work in the first half of 2021, while the second half of the work arrangement.   Commercial Director Liu Tao presided over the meeting and made a brief report on the achievements of marketing work in the first half of the year. As of June 30, 2021, the revenue of British and German Biomoney has completed 77% of the annual target, and the contract amount has completed 91% of the annual target, taking the lead in achieving double half of the double target.   General Manager Su Xiaodong first affirmed the achievements of the Yingde biological team, praised the relevant personnel and departments for their outstanding work in the first half of the year, and encouraged everyone to continue to carry forward the spirit of overcoming difficulties, laying a solid foundation for the next work. He stressed that the current biopharmaceutical industry is facing opportunities and challenges, we must adhere to customer first, strengthen project management, ensure quality and progress, and improve service capabilities.       Wang Hongli, executive deputy general manager, combined with the successful experience and existing problems in the first half of the company's operation, discussed and proposed a number of management measures with the heads of various departments and districts, aiming to strengthen internal management, optimize the allocation of personnel and materials, improve efficiency and quality, and better serve industry customers.   The sales director and sales manager of each area make marketing work reports respectively, and discuss with the management team the improvement of problems in the work and the improvement of customer service satisfaction. After the meeting, the sales team shared the successful experience and methods of the work in the form of a tea party for everyone, and the sharing will continue until late at night.   We are halfway through 2021. In the next work, Yingde Bio-Ding will take serving users in the biopharmaceutical industry as its mission, and then start to create more brilliant achievements.

12

2021

/

07

< 12 >

SAF Coolest v1.2 设置面板TDZSX-ZBQV-EXXZE-AFA

修改浏览器滑块样式： 4px,4px,#f00
营业执照及SEO链接： Business License

无数据提示

Sorry, the current column has no content for the time being.!

You can view other columns or returnHome Page

SVG图标库请自行添加图标，用div包起来，并命名使用